한글목차

세계의 암 면역치료 시장 규모는 2024년에 1,377억 달러에 달하며, 2033년에는 2,617억 4,000만 달러에 달할 것으로 예측되며, 2025-2033년의 예측 기간 중 CAGR은 7.9%로 전망되고 있습니다.

면역종양학이라고도 불리는 암 면역치료는 암을 예방, 관리, 제거하기 위해 신체의 면역체계를 활용하는 암 치료 접근법입니다. 면역체계가 암세포를 식별하고 보다 효과적으로 표적화할 수 있는 능력을 강화합니다. 이 방법은 종양 세포에 존재하는 고유한 항원을 이용하는 것으로, 항원이 적절히 식별되면 면역체계가 이를 인식하고 공격할 수 있게 됩니다. 이 시장에는 면역관문억제제, 단일 클론 항체, 암 백신, CAR-T 세포 치료, 사이토카인 등 몇 가지 주요 치료 접근법이 포함됩니다.

암 발병률 증가는 암 면역치료 시장의 성장 촉진요인입니다. 폐암, 유방암, 대장암 등의 유병률은 지속적으로 증가하고 있으며, 특히 국제암연구소가 2022년 전 세계에서 1,998만 건의 암이 새로 보고될 것으로 예상함에 따라 보다 효과적이고 표적화된 치료 옵션에 대한 요구가 증가하고 있습니다.

또한 미국 국립보건원에 따르면 2025년까지 미국에서만 204만 명의 신규 암 환자가 발생할 것으로 예상하고 있습니다. 특히 폐암은 여전히 세계에서 가장 많이 진단되는 암이며, 암 관련 사망의 주요 원인으로 250만 명에 육박하고 있습니다. 이러한 모든 요인들이 세계 암 면역치료제 시장을 주도하고 있습니다.

이러한 암 환자의 놀라운 증가는 면역치료에 대한 수요를 촉진하고 있습니다. 면역치료는 표적화된 특성과 낮은 독성으로 인해 화학요법과 같은 기존 치료법을 대체할 수 있는 효과적인 치료법으로 점점 더 주목받고 있습니다. 암의 부담이 증가함에 따라 혁신적인 치료법에 대한 요구가 가속화되고 있으며, 이는 연구 투자 증가와 새로운 면역요법 개발에 박차를 가하고 있습니다. 이러한 요인들은 향후 암 면역치료제 시장 확대에 박차를 가할 것으로 예상됩니다.

면역치료의 높은 치료비용이 암 면역치료 시장의 성장을 저해할 것으로 예상됩니다. 실험적 암 면역요법의 전체 치료 비용은 평균 3만 달러에서 4만 달러에 달하므로 많은 환자들이 이러한 치료법을 사용하는 데 있으며, 경제적 장벽에 직면할 수 있습니다. 이러한 고비용은 환자에게 큰 부담을 줄 뿐만 아니라 의료 시스템과 보험 프로바이더에게도 부담이 될 수 있습니다.

일부 면역요법 치료 요법은 치료 기간이 길어지거나 장기간에 걸쳐 여러 번 투여해야 하므로 환자의 총 비용은 더욱 증가하게 됩니다. 지속적인 비용 부담은 개인과 의료 서비스 프로바이더 모두에게 감당하기 어려운 문제입니다. 결과적으로, 이러한 치료의 경제성 여부는 치료의 보급을 제한하고, 시장 침투를 지연시키며, 이러한 첨단 치료의 혜택을 누릴 수 있는 환자들의 접근성을 떨어뜨릴 수 있습니다. 이러한 요인들은 세계 암 면역치료 시장의 잠재적 성장을 제한하는 요인으로 작용할 수 있습니다.

세계의 암 면역치료 시장에 대해 조사했으며, 시장의 개요와 제품 유형별, 적응증별, 지역별 동향, 경쟁 구도 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.

목차

제1장 시장의 서론과 범위

제2장 경영자 인사이트와 주요 포인트

제3장 시장 역학

• 영향요인
  • 촉진요인
  • 억제요인
  • 기회
  • 영향 분석

제4장 전략적 인사이트와 업계 전망

• 시장의 리더와 파이오니어
• CXO의 시점
• 최신 개발과 브레이크스루
• 사례 연구/진행중인 조사
• 규제와 상환의 상황
• Porter's Five Forces 분석
• 공급망 분석
• 특허 분석
• SWOT 분석
• 미충족 요구와 갭
• 시장 진출과 확대를 위한 추천 전략
• 시나리오 분석 베스트 케이스, 베이스 케이스, 워스트 케이스 예측
• 가격 분석과 가격 동향
• 주요 오피니언 리더

제5장 암 면역치료 시장(제품 유형별)

• 면역 체크포인트 저해제
• 모노클로널 항체
• 사이토카인
• 암 백신
• 양자 세포치료
• 종양용해성 바이러스
• 기타

제6장 암 면역치료 시장(적응증별)

• 비소세포 폐암(NSCLC)
• 흑색종
• 대장암
• 신세포암
• 유방암
• 방광암
• 기타

제7장 암 면역치료 시장, 지역별 시장 분석과 성장 기회

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 스페인
  • 이탈리아
  • 기타
• 라틴아메리카
  • 브라질
  • 아르헨티나
  • 기타
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 한국
  • 기타
• 중동 및 아프리카

제8장 경쟁 구도와 시장 포지셔닝

• 경쟁 구도의 개요와 주요 시장 참여 기업
• 시장 점유율 분석과 포지셔닝 매트릭스
• 전략적 파트너십, 합병·인수
• 제품 포트폴리오와 혁신의 주요 발전
• 기업 벤치마킹

제9장 기업 개요

• Amgen Inc.
• 회사 개요
• 제품 포트폴리오
• 재무 개요
• 주요 발전
• SWOT 분석
• F. Hoffmann-La Roche Ltd
• Bristol-Myers Squibb Company
• Merck &Co., Inc.
• AstraZeneca
• Pfizer Inc.
• Johnson &Johnson Services, Inc.
• Incyte
• Dendreon Pharmaceuticals LLC.
• Kite Pharma, Inc.

제10장 가정과 조사 방법

제11장 부록

영문목차

The global cancer immunotherapy market reached US$ 137.70 billion in 2024 and is expected to reach US$ 261.74 billion by 2033, growing at a CAGR of 7.9% during the forecast period of 2025-2033.

Cancer immunotherapy, also called immuno-oncology, is a cancer treatment approach that leverages the body's immune system to prevent, manage, and eliminate cancer. It enhances the immune system's ability to identify and target cancer cells more effectively. This method takes advantage of the unique antigens present in tumor cells, allowing the immune system to recognize and attack them once these antigens are properly identified. This market includes several key treatment approaches, such as immune checkpoint inhibitors, monoclonal antibodies, cancer vaccines, CAR-T cell therapies, and cytokines.

Market Dynamics: Drivers & Restraints

Increasing Incidence of Cancer Cases

The increasing incidence of cancer is a key driver for the growth of the cancer immunotherapy market. As the prevalence of cancers such as lung, breast, and colorectal continues to rise, particularly with 19.98 million new cases reported globally in 2022 by the International Agency for Research on Cancer, there is a growing need for more effective and targeted treatment options.

Additionally, according to the National Institutes of Health, there will be 2.04 million new cancer cases in the U.S. alone by 2025. Lung cancer, in particular, remains the most commonly diagnosed and the leading cause of cancer-related deaths worldwide, with nearly 2.5 million cases. All these factors drive the global cancer immunotherapy market.

This alarming rise in cancer cases is driving demand for immunotherapies, which are increasingly seen as an effective alternative to traditional treatments like chemotherapy due to their targeted nature and lower toxicity. As the burden of cancer grows, the need for innovative therapies accelerates, spurring increased investment in research and the development of new immunotherapy options. Thus, the above factor is expected to continue fueling the expansion of the cancer immunotherapy market.

High Cost of Treatment

The high cost of immunotherapy treatments is expected to hinder the growth of the cancer immunotherapy market. With a full course of experimental cancer immunotherapy averaging between $30,000 and $40,000, many patients may face financial barriers to accessing these therapies. This high cost not only places a significant burden on patients but also strains healthcare systems and insurance providers.

Some immunotherapy treatment regimens require extended treatment periods or multiple doses over time, further increasing overall costs for patients. The ongoing cost burden can be difficult to manage for both individuals and healthcare providers. As a result, the affordability of these treatments may limit their widespread adoption, slow market penetration, and reduce access for patients who could benefit from these advanced therapies. Thus, the above factors could be limiting the global cancer immunotherapy market's potential growth.

Segment Analysis

The global cancer immunotherapy market is segmented based on product type, indication, and region.

Product Type:

The monoclonal antibodies segment in product type is expected to dominate the global cancer immunotherapy market with the highest market share

Monoclonal antibodies (mAbs) are laboratory-made proteins that mimic the immune system's ability to fight harmful pathogens. In cancer immunotherapy, these antibodies specifically target cancer cells by recognizing unique antigens on their surface.

The monoclonal antibodies (mAbs) segment is primarily driven by extensive research and development investments, technological advancements, and their effectiveness in treating various types of cancer. Monoclonal antibodies are widely used in targeting specific cancer cells while minimizing damage to healthy tissues, making them a preferred choice in immunotherapy. The market is also expanding due to increasing cancer prevalence, rising awareness of immunotherapy treatments, and regulatory approvals that accelerate the availability of new drugs.

Furthermore, key players' strategies, such as partnerships and collaborations, would propel this segment's growth in the market. For instance, in March 2023, BioNTech SE and OncoC4, Inc. entered into a global licensing and collaboration agreement to develop and commercialize ONC-392, a next-generation anti-CTLA-4 monoclonal antibody.

This agreement gives BioNTech exclusive worldwide rights to further advance this experimental cancer treatment, either as a standalone therapy (monotherapy) or in combination with other treatments. These factors have solidified the segment's position in the global cancer immunotherapy market.

Geographical Analysis

North America is expected to hold a significant position in the global cancer immunotherapy market, with the highest market share

North America is expected to maintain its dominance in the cancer immunotherapy market throughout the forecast period, driven by the region's high cancer incidence and growing demand for innovative treatments. The American Cancer Society projects 226,650 new lung cancer cases in 2025 alone, contributing to an increased need for cancer immunotherapies. With this, the number of individuals who approach cancer immunotherapy is also expected to rise.

In addition to the increasing number of cancer cases, North America benefits from strong governmental support and significant funding directed at cancer research. This funding fosters the development of new therapies and accelerates their introduction to the market. Moreover, the region is a global leader in research and development, with major pharmaceutical companies and renowned research institutions driving continuous progress in oncology treatments.

North America's regulatory environment also plays a key role in this dominance. For instance, in May 2024, Amgen received accelerated approval of IMDELLTRA (tarlatamab-dlle), a breakthrough immunotherapy for extensive-stage small cell lung cancer (ES-SCLC) patients who have progressed after platinum-based chemotherapy. This approval highlights the region's capability to fast-track innovative cancer treatments. With these factors, North America is expected to remain a dominant force in the global cancer immunotherapy market, driving both demand and development for new cancer therapies.

Competitive Landscape

The major global players in the cancer immunotherapy market include Amgen Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Merck & Co., Inc., AstraZeneca, Pfizer Inc., Johnson & Johnson Services, Inc., Incyte, Dendreon Pharmaceuticals LLC., and Kite Pharma, Inc., among others.

Key Developments

• In September 2024, Roche received the U.S. Food and Drug Administration (FDA) approval for Tecentriq HybrezaTM (atezolizumab and hyaluronidase-tqjs), the first and only the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy.
• In January 2024, Boehringer Ingelheim and 3T Biosciences entered into a new strategic collaboration and licensing agreement focused on discovering and developing next-generation life-changing cancer immunotherapies.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global cancer immunotherapy market report delivers a detailed analysis with 54 key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Product Type
• 2.4. Snippet by Indication
• 2.5. Snippet by Region

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Increasing Incidence of Cancer Cases
    • 3.1.1.2. Rising Investment and Funding
  • 3.1.2. Restraints
    • 3.1.2.1. High Cost of Treatment
    • 3.1.2.2. Side Effects Associated with Treatment
  • 3.1.3. Opportunity
    • 3.1.3.1. Rising Number of Clinical Trials
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with the largest-selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. CXO Perspectives
• 4.3. Latest Developments and Breakthroughs
• 4.4. Case Studies/Ongoing Research
• 4.5. Regulatory and Reimbursement Landscape
  • 4.5.1. North America
  • 4.5.2. Europe
  • 4.5.3. Asia Pacific
  • 4.5.4. Latin America
  • 4.5.5. Middle East & Africa
• 4.6. Porter's Five Forces Analysis
• 4.7. Supply Chain Analysis
• 4.8. Patent Analysis
• 4.9. SWOT Analysis
• 4.10. Unmet Needs and Gaps
• 4.11. Recommended Strategies for Market Entry and Expansion
• 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.13. Pricing Analysis and Price Dynamics
• 4.14. Key Opinion Leaders

5. Cancer Immunotherapy Market, By Product Type

• 5.1. Introduction
  • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 5.1.2. Market Attractiveness Index, By Product Type
• 5.2. Immune Checkpoint Inhibitors*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.2.3. Atezolizumab
  • 5.2.4. Avelumab
  • 5.2.5. Nivolumab
  • 5.2.6. Pembrolizumab
  • 5.2.7. Durvalumab
  • 5.2.8. Ipilimumab
  • 5.2.9. Others
• 5.3. Monoclonal Antibodies
• 5.4. Cytokines
• 5.5. Cancer Vaccines
  • 5.5.1. Preventive Vaccines
  • 5.5.2. Therapeutic Vaccines
• 5.6. Adoptive Cell Therapy
  • 5.6.1. Tumor Infiltrating Lymphocyte (TIL) Therapy
  • 5.6.2. Engineered T-Cell Receptor (TCR) Therapy
  • 5.6.3. Chimeric Antigen Receptor (CAR) T Cell Therapy
  • 5.6.4. Natural Killer (NK) Cell Therapy
• 5.7. Oncolytic Virus
• 5.8. Other Immunotherapies

6. Cancer Immunotherapy Market, By Indication

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 6.1.2. Market Attractiveness Index, By Indication
• 6.2. Non-Small Cell Lung Cancer (NSCLC)*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Melanoma
• 6.4. Colorectal Cancer
• 6.5. Renal Cell Carcinoma
• 6.6. Breast Cancer
• 6.7. Bladder Cancer
• 6.8. Others

7. Cancer Immunotherapy Market, By Regional Market Analysis and Growth Opportunities

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 7.1.2. Market Attractiveness Index, By Region
• 7.2. North America
  • 7.2.1. Introduction
  • 7.2.2. Key Region-Specific Dynamics
  • 7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.2.5.1. U.S.
    • 7.2.5.2. Canada
    • 7.2.5.3. Mexico
• 7.3. Europe
  • 7.3.1. Introduction
  • 7.3.2. Key Region-Specific Dynamics
  • 7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.3.5.1. Germany
    • 7.3.5.2. U.K.
    • 7.3.5.3. France
    • 7.3.5.4. Spain
    • 7.3.5.5. Italy
    • 7.3.5.6. Rest of Europe
• 7.4. Latin America
  • 7.4.1. Introduction
  • 7.4.2. Key Region-Specific Dynamics
  • 7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.4.5.1. Brazil
    • 7.4.5.2. Argentina
    • 7.4.5.3. Rest of Latin America
• 7.5. Asia-Pacific
  • 7.5.1. Introduction
  • 7.5.2. Key Region-Specific Dynamics
  • 7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.5.5.1. China
    • 7.5.5.2. India
    • 7.5.5.3. Japan
    • 7.5.5.4. South Korea
    • 7.5.5.5. Rest of Asia-Pacific
• 7.6. Middle East and Africa
  • 7.6.1. Introduction
  • 7.6.2. Key Region-Specific Dynamics
  • 7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

8. Competitive Landscape and Market Positioning

• 8.1. Competitive Overview and Key Market Players
• 8.2. Market Share Analysis and Positioning Matrix
• 8.3. Strategic Partnerships, Mergers & Acquisitions
• 8.4. Key Developments in Product Portfolios and Innovations
• 8.5. Company Benchmarking

9. Company Profiles

• 9.1. Amgen Inc.*
  • 9.1.1. Company Overview
  • 9.1.2. Product Portfolio
    • 9.1.2.1. Product Description
    • 9.1.2.2. Product Key Performance Indicators (KPIs)
    • 9.1.2.3. Historic and Forecasted Product Sales
    • 9.1.2.4. Product Sales Volume
  • 9.1.3. Financial Overview
    • 9.1.3.1. Company Revenue
    • 9.1.3.2. Geographical Revenue Shares
    • 9.1.3.3. Revenue Forecasts
  • 9.1.4. Key Developments
    • 9.1.4.1. Mergers & Acquisitions
    • 9.1.4.2. Key Product Development Activities
    • 9.1.4.3. Regulatory Approvals, etc.
  • 9.1.5. SWOT Analysis
• 9.2. F. Hoffmann-La Roche Ltd
• 9.3. Bristol-Myers Squibb Company
• 9.4. Merck & Co., Inc.
• 9.5. AstraZeneca
• 9.6. Pfizer Inc.
• 9.7. Johnson & Johnson Services, Inc.
• 9.8. Incyte
• 9.9. Dendreon Pharmaceuticals LLC.
• 9.10. Kite Pharma, Inc.

LIST NOT EXHAUSTIVE

10. Assumptions and Research Methodology

• 10.1. Data Collection Methods
• 10.2. Data Triangulation
• 10.3. Forecasting Techniques
• 10.4. Data Verification and Validation

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us